Clinical trials: Graft vs Host Disease
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Long-term Extension Study of PCI-32765 (Ibrutinib)
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- CAN3001 (NCT01804686)
- Testing
- Ibrutinib
- Where
- 175 sites in United States, Argentina and 28 more
- Volunteers
- 539 people
- Sponsor
- Janssen Research & Development, LLC
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Graft Versus Host Disease
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
Background: This study follows people who have had, or will soon have, a transplant using stem cells from another person. This is known as an allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT03602599
- Where
- United States
- Volunteers
- 190 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Hematopoietic Stem Cell Transplantation (HSCT), Malnutrition (Calorie)
Nutritional Intervention for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
This is a multi-center observational study. The study aims to explore the effect of enteral nutritional support on nutritional status and clinical outcomes in patients after hematopoietic stem cell transplantation.
- Trial name
- HSCT-NUT (NCT07850375)
- Testing
- Enteral Nutritional Suspension (TP-MCT), Routine nutritional guidance, Biospecimen-Stool Sample Collection
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
The goal of this observational study is to investigate the development of vulvovaginal graft-versus-host- disease (GVHD), an under-reported and under-recognized manifestation of chronic GVHD.
- Trial name
- NCT06649201
- Testing
- Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Case Comprehensive Cancer Center
Graft vs Host Disease
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Background: Chronic graft-versus-host disease (cGVHD) is an immune system disorder that can occur in people who have had a stem cell transplant. cGVHD can affect multiple organs and increase risk of disability and death.
- Trial name
- NCT05531786
- Testing
- Pacritinib
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Bone Marrow Transplant Complications, Graft-versus-Host Disease
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
The goal of this study is to demonstrate the efficacy of a multidisciplinary group-based telehealth intervention (HORIZONS) compared to minimally enhanced usual care for improving self-management and quality of life for…
- Trial name
- HORIZONS (NCT06910969)
- Testing
- HORIZONS Intervention, Minimally enhanced usual care
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Massachusetts General Hospital
Chronic Graft Versus Host Disease
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant.
- Trial name
- NCT07011810
- Testing
- Axatilimab, Biospecimen Collection, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid…
- Trial name
- NCT04744116
- Testing
- Cellular Therapy, Ruxolitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Graft Versus Host Disease
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
This is an open-label, single group, Phase 1/2, 1-arm study for treatment of children aged 1 to <18 years with active moderate-to-severe cGVHD that is refractory to or recurred after at least 2 prior lines of systemic therapy for…
- Trial name
- schoolROCK (NCT07116031)
- Testing
- Belumosudil
- Where
- 35 sites in United States, Belgium and 11 more
- Volunteers
- 37 people
- Sponsor
- Sanofi
Chronic Graft vs. Host Disease, GVHD
Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (cGVHD) is a condition that can develop after a stem cell transplant. It occurs when donor immune cells attack the body's tissues.
- Conditions
- Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
- Trial name
- NCT07728708
- Testing
- Axatilimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Acute Leukemia in Remission, Myelodysplastic Syndromes
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma
- Trial name
- TMF-Allo (NCT04935684)
- Testing
- Fecal Microbiota Transplantation
- Where
- 20 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Allogeneic Disease, GVH - Graft Versus Host Reaction
To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids
Phase III randomized double-blinded trial designed to compare the efficacy of the addition of MTX to current standard acute GVHD first-line treatment with corticosteroids.
- Conditions
- Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute, Stem Cell Transplant Complications
- Trial name
- MTX-aGVHD (NCT03371667)
- Testing
- Methotrexate
- Where
- France
- Volunteers
- 104 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Graft vs Host Disease
Chronic GVHD Response Measures Validation
The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD).
- Trial name
- NCT01902576
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Graft Versus Host Disease
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease.
- Trial name
- NCT05996627
- Testing
- Belumosudil, Biospecimen Collection, Electronic Health Record Review
- Where
- 5 sites in United States
- Volunteers
- 82 people
- Sponsor
- Fred Hutchinson Cancer Center
Steroid-refractory Acute Graft Versus Host Disease
Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
- Trial name
- NCT06462469
- Testing
- Ruxolitinib
- Where
- 9 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Graft vs Host Disease, Mesenchymal Stem Cell Transplantation
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host…
- Trial name
- NCT07826676
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- 4 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Severe Combined Immunodeficiency
Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)
Infants with severe combined immunodeficiency (SCID) have a profound decrease in number and function of immune cells, and therefore remain highly vulnerable to infection. If not corrected this often leads to death.
- Trial name
- NCT03597594
- Testing
- Anti-thymocyte globulin (rabbit), Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- St. Jude Children's Research Hospital
Chronic Graft Versus Host Disease
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Participants will be randomized 1:1 to receive either belumosudil or Best Available Therapy (BAT), with stratification based on baseline cGVHD severity as defined by the 2014◦NIH consensus criteria (moderate versus severe), use…
- Trial name
- NCT07771439
- Testing
- Belumosudil, Best available therapy (BAT)
- Volunteers
- 356 people
- Sponsor
- Sanofi
Graft Versus Host Disease
Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab (Protocol R-GVHD)
The main objective of the study is to improve the response rate (complete and partial remission) at 12 months after diagnosis of chronic Chronic Graft Versus Host Disease (GVHD) and treatment with the combination of ciclosporine…
- Trial name
- R-GVHD (NCT01135641)
- Testing
- Rituximab, Ciclosporine, Corticosteroids
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Nantes University Hospital